STOCK TITAN

Spectral AI, Inc. - MDAI STOCK NEWS

Welcome to our dedicated page for Spectral AI news (Ticker: MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.

Spectral AI, Inc. (Nasdaq: MDAI) is an artificial intelligence company dedicated to advancing medical diagnostics, particularly in wound care. The company's flagship product, the DeepView™ System, is a cutting-edge multispectral imaging (MSI) device designed to assist physicians in making accurate and timely treatment decisions. This innovative technology leverages proprietary algorithms to differentiate between damaged and healthy tissue, producing critical Day One healing assessments within seconds.

Spectral AI's DeepView System has received FDA Breakthrough Device Designation due to its potential to significantly improve patient outcomes. The primary focus of the company lies in the research and development of this system. Notably, a substantial portion of its funding comes from the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.

In recent developments, Spectral AI was honored with the Commitment to Quality Achievement Award by the Texas Manufacturer Assistance Center (TMAC) for their attainment of the UKCA Mark. This accolade underscores the company’s dedication to maintaining the highest standards of quality while working towards the commercialization of DeepView technology.

The company frequently updates its stakeholders through conference calls and presentations, which can be accessed via the investor relations section of its website. This proactive communication strategy ensures transparency and keeps investors well-informed about the company's progress and financial health.

Investor Relations Contacts:

Devin Sullivan, Managing Director at The Equity Group, can be reached at dsullivan@equityny.com.

Conor Rodriguez, Analyst at The Equity Group, can be contacted at crodriguez@equityny.com.

Media Contacts:

David Schull of Russo Partners can be reached at david.schull@russopartnersllc.com or (858) 717-2310.

Rhea-AI Summary

Spectral AI, Inc. (Nasdaq: MDAI) received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center for their UKCA Mark Attainment. The award recognizes the company's leadership in the Texas Manufacturing space and their dedication to innovation in wound care through DeepView™ technology. TMAC, associated with MEP-NIST, supports Texas manufacturers with business consulting, technology implementation, workforce development, and strategic planning.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) has scheduled its 2024 first quarter financial results release for May 7, 2024. The company specializes in AI for medical diagnostics in wound care, aiming for faster and more precise treatment decisions. Investors can join the conference call at 5:00 pm Eastern Time to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary
Spectral AI appoints Erich Spangenberg as CEO of its health care IP-focused subsidiary, Spectral IP, aiming to unlock additional value for MDAI shareholders through potential spin-off. Spangenberg's IP monetization expertise and investment plans highlight the company's strategic move towards IP-related opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. appoints Jeremiah A. Sparks as Chief Commercialization Officer to drive commercialization of DeepView, an innovative wound management solution. Sparks brings over 20 years of medical device marketing experience, including global marketing and business strategy. His track record includes successful market assessments, commercialization plans, and product launches at major companies like Johnson & Johnson and Allergan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.39%
Tags
management AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) expects its 2023 Research & Development revenue of $18.1 million to increase to $28.0 million in 2024. Commercialization for DeepView AI®-Burn indication in the UK is underway, with revenue expected in 2H 2024. The company plans additional regulatory submissions in the US and UK for DeepView™ System burn and diabetic foot ulcer indications. Spectral AI highlights progress in product development, clinical trials, and financial results, aiming for commercial revenue across multiple platforms within the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) secures a $30.0 million prepaid advance and standby equity purchase agreement to support commercialization and research activities. The agreement with a long-only investor includes a fixed conversion price of $3.16 and provides flexibility for additional draws. CEO Peter M. Carlson highlights the importance of this funding for strategic imperatives and commercialization initiatives, emphasizing recent milestones in the U.K. and the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.24%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a $1 million investment from its largest shareholder into its subsidiary Spectral IP, focusing on advancing intellectual property in the AI ecosystem. The investment aims to unlock additional value for shareholders and accelerate innovation in medical diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.66%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) will report financial results for Q4 and full year 2023 on March 27, 2024. The company focuses on AI medical diagnostics for wound care. Investors can join the conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.05%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) secures a new $500,000 contract with the Defense Health Agency and the US Army Medical Material Development Activity for the development of the handheld version of DeepView™ Wound Imaging System. The Company has received over $149 million in non-dilutive financing in the past six months, bringing the total government support to over $250 million. The contract aims to optimize the device's functionality and size for combat readiness and potential use in home health care, reinforcing Spectral AI's position as a leader in AI-driven healthcare innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) forms a subsidiary to focus on advancing intellectual property in the AI healthcare sector, aiming to enhance shareholder value through patents and trade secrets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
AI

FAQ

What is the current stock price of Spectral AI (MDAI)?

The current stock price of Spectral AI (MDAI) is $1.89 as of December 20, 2024.

What is the market cap of Spectral AI (MDAI)?

The market cap of Spectral AI (MDAI) is approximately 39.7M.

What does Spectral AI, Inc. specialize in?

Spectral AI specializes in AI-based medical diagnostics, particularly focusing on wound care through their DeepView System.

What is the DeepView System?

The DeepView System is a multispectral imaging device that uses AI algorithms to distinguish between damaged and healthy tissue, aiding in quicker and more accurate treatment decisions.

Has the DeepView System received any regulatory recognition?

Yes, the DeepView System has received FDA Breakthrough Device Designation.

Where does Spectral AI get its research funding?

A substantial portion of Spectral AI's funding comes from the Biomedical Advanced Research and Development Authority (BARDA).

What recent award has Spectral AI received?

Spectral AI recently received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center.

How can investors stay updated on Spectral AI's progress?

Investors can stay updated through conference calls and presentations available on the investor relations section of the company's website.

Who are the media contacts for Spectral AI?

David Schull of Russo Partners, reachable at david.schull@russopartnersllc.com or (858) 717-2310, is the media contact.

What is the role of BARDA in Spectral AI's operations?

BARDA provides essential research and development funding for Spectral AI's projects.

What kind of assessments does the DeepView System provide?

The DeepView System provides Day One healing assessments, allowing for accurate and timely treatment decisions.

Who are the investor relations contacts at Spectral AI?

Devin Sullivan, Managing Director, and Conor Rodriguez, Analyst, both at The Equity Group, are the investor relations contacts.

Spectral AI, Inc.

Nasdaq:MDAI

MDAI Rankings

MDAI Stock Data

39.66M
12.12M
42.18%
15.82%
4.31%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
DALLAS